Showing results (101-110 of 113) with videos related to
Sort By:
Pageof 12
Thoracic Cancer|May 31, 2019
Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational studyHongge Liang, Xia Song, Yuhui Zhang, et al.Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.JAMA|December 5, 2023
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical TrialJianming Xu, Haiping Jiang, Yueyin Pan, et al.The Lancet. Respiratory Medicine|September 12, 2024
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trialBaohui Han, Trevor Feinstein, Yuankai Shi, et al.Journal of Hematology & Oncology|November 12, 2024
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trialFeng Bi, Jian Dong, Chuan Jin, et al.BMC Medicine|February 24, 2023
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Jianhua Chen, Helong Zhang, et al.Hematological Oncology|July 20, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trialYuankai Shi, Qingyuan Zhang, Xiaonan Hong, et al.Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.European Radiology|February 6, 2020
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trialZhigang Wei, Xia Yang, Xin Ye, et al.Cancer Communications (London, England)|April 2, 2026
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.Pageof 12